These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 30591655)

  • 1. Effects of SAHA and EGCG on Growth Potentiation of Triple-Negative Breast Cancer Cells.
    Lewis KA; Jordan HR; Tollefsbol TO
    Cancers (Basel); 2018 Dec; 11(1):. PubMed ID: 30591655
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SAHA and EGCG Promote Apoptosis in Triple-negative Breast Cancer Cells, Possibly Through the Modulation of cIAP2.
    Steed KL; Jordan HR; Tollefsbol TO
    Anticancer Res; 2020 Jan; 40(1):9-26. PubMed ID: 31892549
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells.
    Min A; Im SA; Kim DK; Song SH; Kim HJ; Lee KH; Kim TY; Han SW; Oh DY; Kim TY; O'Connor MJ; Bang YJ
    Breast Cancer Res; 2015 Mar; 17():33. PubMed ID: 25888415
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Suberoylanilide hydroxamic acid-induced specific epigenetic regulation controls Leptin-induced proliferation of breast cancer cell lines.
    Feng X; Han H; Zou D; Zhou J; Zhou W
    Oncotarget; 2017 Jan; 8(2):3364-3379. PubMed ID: 27926517
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activation of FOXO3a by the green tea polyphenol epigallocatechin-3-gallate induces estrogen receptor alpha expression reversing invasive phenotype of breast cancer cells.
    Belguise K; Guo S; Sonenshein GE
    Cancer Res; 2007 Jun; 67(12):5763-70. PubMed ID: 17575143
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Novel Combinatorial Epigenetic Therapy Using Resveratrol and Pterostilbene for Restoring Estrogen Receptor-α (ERα) Expression in ERα-Negative Breast Cancer Cells.
    Kala R; Tollefsbol TO
    PLoS One; 2016; 11(5):e0155057. PubMed ID: 27159275
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Suberoylanilide hydroxamic acid (SAHA) promotes the epithelial mesenchymal transition of triple negative breast cancer cells via HDAC8/FOXA1 signals.
    Wu S; Luo Z; Yu PJ; Xie H; He YW
    Biol Chem; 2016 Jan; 397(1):75-83. PubMed ID: 26431101
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epigenetic reprogramming of epithelial mesenchymal transition in triple negative breast cancer cells with DNA methyltransferase and histone deacetylase inhibitors.
    Su Y; Hopfinger NR; Nguyen TD; Pogash TJ; Santucci-Pereira J; Russo J
    J Exp Clin Cancer Res; 2018 Dec; 37(1):314. PubMed ID: 30547810
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces differentiation of human breast cancer cells.
    Munster PN; Troso-Sandoval T; Rosen N; Rifkind R; Marks PA; Richon VM
    Cancer Res; 2001 Dec; 61(23):8492-7. PubMed ID: 11731433
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anticancer effects of suberoylanilide hydroxamic acid in esophageal squamous cancer cells in vitro and in vivo.
    Tzao C; Jin JS; Chen BH; Chung HY; Chang CC; Hsu TY; Sun GH
    Dis Esophagus; 2014; 27(7):693-702. PubMed ID: 24033428
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epigenetic-based combinatorial resveratrol and pterostilbene alters DNA damage response by affecting SIRT1 and DNMT enzyme expression, including SIRT1-dependent γ-H2AX and telomerase regulation in triple-negative breast cancer.
    Kala R; Shah HN; Martin SL; Tollefsbol TO
    BMC Cancer; 2015 Oct; 15():672. PubMed ID: 26459286
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Suberoylanilide hydroxamic acid as a potential therapeutic agent for human breast cancer treatment.
    Huang L; Pardee AB
    Mol Med; 2000 Oct; 6(10):849-66. PubMed ID: 11126200
    [TBL] [Abstract][Full Text] [Related]  

  • 13. (-)-Epigallocatechin-3-gallate reverses the expression of various tumor-suppressor genes by inhibiting DNA methyltransferases and histone deacetylases in human cervical cancer cells.
    Khan MA; Hussain A; Sundaram MK; Alalami U; Gunasekera D; Ramesh L; Hamza A; Quraishi U
    Oncol Rep; 2015 Apr; 33(4):1976-84. PubMed ID: 25682960
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of lymphangiogenic factor VEGF-C expression and production by the histone deacetylase inhibitor suberoylanilide hydroxamic acid in breast cancer cells.
    Cheng HT; Hung WC
    Oncol Rep; 2013 Mar; 29(3):1238-44. PubMed ID: 23242251
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Co-targeting poly(ADP-ribose) polymerase (PARP) and histone deacetylase (HDAC) in triple-negative breast cancer: Higher synergism in BRCA mutated cells.
    Marijon H; Lee DH; Ding L; Sun H; Gery S; de Gramont A; Koeffler HP
    Biomed Pharmacother; 2018 Mar; 99():543-551. PubMed ID: 29902865
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Histone deacetylase inhibitor SAHA induces ERalpha degradation in breast cancer MCF-7 cells by CHIP-mediated ubiquitin pathway and inhibits survival signaling.
    Yi X; Wei W; Wang SY; Du ZY; Xu YJ; Yu XD
    Biochem Pharmacol; 2008 May; 75(9):1697-705. PubMed ID: 18342836
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (Vorinostat, SAHA) profoundly inhibits the growth of human pancreatic cancer cells.
    Kumagai T; Wakimoto N; Yin D; Gery S; Kawamata N; Takai N; Komatsu N; Chumakov A; Imai Y; Koeffler HP
    Int J Cancer; 2007 Aug; 121(3):656-65. PubMed ID: 17417771
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Inhibitory Effect of (-)-Epigallocatechin-3-Gallate on Breast Cancer Progression via Reducing
    Sheng J; Shi W; Guo H; Long W; Wang Y; Qi J; Liu J; Xu Y
    Molecules; 2019 Aug; 24(16):. PubMed ID: 31404982
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interplay between Epigenetics, Expression of Estrogen Receptor- α, HER2/ERBB2 and Sensitivity of Triple Negative Breast Cancer Cells to Hormonal Therapy.
    Ramadan WS; Vazhappilly CG; Saleh EM; Menon V; AlAzawi AM; El-Serafi AT; Mansour W; El-Awady R
    Cancers (Basel); 2018 Dec; 11(1):. PubMed ID: 30583472
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Suberoylanilide hydroxamic acid increases anti-cancer effect of tumor necrosis factor-α through up-regulation of TNF receptor 1 in lung cancer cells.
    You BR; Han BR; Park WH
    Oncotarget; 2017 Mar; 8(11):17726-17737. PubMed ID: 28099148
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.